Clinical trials: Familial Primary Pulmonary Hypertension
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Hormonal, Metabolic, and Signaling Interactions in PAH
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
- Trial name
- NCT01884051
- Where
- United States
- Volunteers
- 1,899 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension
: Vascular Function in Health and Disease
Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions.
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
- Trial name
- NCT02966665
- Testing
- Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- D. Walter Wray
Pulmonary Artery Hypertension
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health…
- Trial name
- NCT03617458
- Testing
- Metformin, mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Artery Hypertension, Right Ventricular Dysfunction
Right Ventricular Pacing in Pulmonary Arterial Hypertension
In pulmonary arterial hypertension (PAH), progressive pulmonary vascular remodeling leads to supraphysiologic right ventricular (RV) afterload.
- Trial name
- NCT04194632
- Testing
- Temporary right ventricular pacing
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Pulmonary Artery Hypertension, Congenital Heart Disease
Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires
Background: A heart catheterization is a diagnostic heart procedure used to measure pressures and take pictures of the blood flow through the heart chambers.
- Conditions
- Pulmonary Artery Hypertension, Congenital Heart Disease, Structural Heart Disease
- Trial name
- NCT03152773
- Testing
- MRI Heart guidewire catheterization
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Artery Hypertension
Sotatercept in Pulmonary Arterial Hypertension
The goal of this clinical trial is to determine whether sotatercept is effective in improving diffusing capacity in patients with pulmonary arterial hypertension.
- Trial name
- NCT07140484
- Testing
- Sotatercept
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of Alberta
PAH, Pulmonary Hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health…
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03626688
- Testing
- Ralinepag
- Where
- 209 sites in United States, Argentina and 31 more
- Volunteers
- 687 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
- Trial name
- NCT05462574
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Vanderbilt University Medical Center
Idiopathic Pulmonary Hypertension
Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension
This study aims to compare the effectiveness and safety of two treatment approaches for patients with severe pulmonary hypertension: standard targeted drug therapy alone, and a combination of standard targeted drugs plus Qishen…
- Trial name
- NCT07604805
- Testing
- Qishen Yiqi Dropping Pills 0.5g Oral Three Times Daily + Targeted Therapy for Pulmonary Arterial Hypertension, Standard Pulmonary Arterial Hypertension (PAH)-Targeted Therapy Alone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangdong Provincial People's Hospital
Idiopathic Pulmonary Arterial Hypertension
Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial
The goal of this research is to investigate the effectiveness of exercise administered via immersive virtual reality in patients with pulmonary hypertension, thereby contributing to the existing literature on this subject.
- Trial name
- NCT07558460
- Testing
- Virtual Reality Group
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Istanbul University - Cerrahpasa
Pulmonary Arterial Hypertension
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
This multicenter, open label, Phase 2a study is designed to evaluate the effect of inhaled RT234 delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with Pulmonary Arterial…
- Trial name
- NCT05343637
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
- Where
- 3 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Respira Therapeutics, Inc.
Postpartum Haemorrhage (PPH), PPH
EVE TRIAL , ALMA SYSTAM
abnormal bleeding after childbirth. This condition is called abnormal bleeding and becomes a condition known as postpartum hemorrhage (PPH) when worsens.
- Conditions
- Postpartum Haemorrhage (PPH), PPH, Postpartum Hemorrhage (Primary)
- Trial name
- EVE (NCT06646653)
- Testing
- Alma System
- Where
- 2 sites in United States, Israel
- Volunteers
- 50 people
- Sponsor
- ResQ Medical Ltd
Pulmonary Artery Hypertension
Endothelial Cell Activation and Total Pulmonary Resistance in PAH
To determine whether changes in endothelial cell dysfunction are associated with changes in total pulmonary resistance in patients with pulmonary arterial hypertension
- Trial name
- NCT06035861
- Testing
- XBD173
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
- Trial name
- RARE-PAH (NCT05584722)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor…
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
- Trial name
- Xenon PAH Bio (NCT06104228)
- Testing
- 129Xe Hyperpolarized
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bastiaan Driehuys
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)
The purpose of this research is to gather information on the safety and effectiveness of a new procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO).
- Conditions
- Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Artery Hypertension
- Trial name
- FETO (NCT03138863)
- Testing
- BALT GoldbBAL2 Detachable Balloon, Catheter System
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rodrigo Ruano
Pulmonary Vascular Disorder, Primary Pulmonary Hypertension
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study investigating the effect of riociguat (MK-4836) in patients with early pulmonary vascular disease.
- Conditions
- Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue
- Trial name
- ESRA (NCT05339087)
- Testing
- Riociguat Oral Tablet
- Where
- 8 sites in Austria, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Heidelberg University
Scleroderma, Pulmonary Artery Hypertension
Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH
This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure).
- Trial name
- CALIPSO (NCT04610788)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Johns Hopkins University
Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
In preparation for a future mechanistic study, investigators now propose to test the specific hypothesis that carnitine consumption is not reduced in PAH, that plasma carnitine levels are stable over time in PAH and that…
- Conditions
- Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases
- Trial name
- NCT04908397
- Testing
- L-carnitine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University Medical Center